Polarean Imaging plc (AIM: POLX), the medical ‑ imaging technology company, with a proprietary drug ‑ device combination product for the magnetic resonance imaging (MRI) market, announces that that it has received notification from a warrant holder to exercise warrants representing 467,733 ordinary shares of £0.00037 each in the capital of the Company ( Ordinary Shares ). The exercise price of the warrants was 15p per warrant. Application will be made for the 467,733 new Ordinary Shares to be admitted to trading on AIM ( Admission ), which is expected to occur at 8.00 a.m. on or around 22 April 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.
+44 (0)20 7710 7600 Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) Nick Adams / Fred Walsh (Corporate Broking) Walbrook PR Paul McManus / Anna Dunphy The Company and its wholly owned subsidiary, Polarean, Inc. (together the Group ) are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (
129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other
+44 (0)20 7710 7600 Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) Nick Adams / Fred Walsh (Corporate Broking) Walbrook PR Paul McManus / Anna Dunphy The Company and its wholly owned subsidiary, Polarean, Inc. (together the Group ) are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (
129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging
Getty Images
January 18, 2021 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in the United States. Its purpose is to assess the diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases in patients previously treated with radiation therapy. The firs